$NERV News

Jefferies Upgrades Minerva Neurosciences to Buy, Raises Price Target to $10

Minerva Neurosciences Q2 Adj. EPS $(0.10) Beats $(0.12) Estimate

CORRECTION: Minerva Neurosciences Establishes $75M At-The-Market Stock Offering Program With Leerink Partners

Minerva Neurosciences Q1 Adj. EPS $(0.17) Misses $(0.13) Estimate

Citizens Initiates Coverage On Minerva Neurosciences with Market Outperform Rating, Announces Price Target of $14

Minerva Neurosciences Says First Patient Screened In Confirmatory Phase 3 Clinical Trial Evaluating Roluperidone As Monotherapy For Treatment Of Negative Symptoms Of Schizophrenia

Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia

Minerva Neurosciences Reveals Data From Its Open-Label Safety Trial Evaluating Roluperidone Co-Administered With Olanzapine At SIRS 2026; Trial Demonstrated No Safety Concerns When Co-Administering Roluperidone And Olanzapine

HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Raises Price Target to $7

Minerva Neurosciences Files Prospectus To Offer Up To $200M In Common Stock, Preferred Stock, Debt, And Warrants

Minerva Neurosciences Q4 Adj. EPS $(0.64) Misses $(0.30) Estimate

Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia - Slideshow

Minerva Neurosciences Spotlights Roluperidone, Lays Out Confirmatory Phase 3 Timeline for Schizophrenia

Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript

Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026

Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors

HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Lowers Price Target to $4

Minerva Neurosciences: Q3 Earnings Snapshot

Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates

Minerva Neurosciences Q3 EPS $(0.36) Misses $(0.35) Estimate